Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Collegium Pharmaceutical Inc    COLL

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2017 12/06/2017 12/07/2017 12/08/2017 12/11/2017 Date
17.74(c) 17.21(c) 18.34(c) 17.7(c) 17.79(c) Last
2 355 317 1 145 470 1 112 343 1 342 032 790 189 Volume
+4.72% -2.99% +6.57% -3.49% +0.51% Change
More quotes
Financials ($)
Sales 2017 27,9 M
EBIT 2017 -74,9 M
Net income 2017 -76,9 M
Finance 2017 107 M
Yield 2017 -
Sales 2018 213 M
EBIT 2018 -12,9 M
Net income 2018 -44,7 M
Finance 2018 71,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 16,9x
EV / Sales2018 2,39x
Capitalization 579 M
More Financials
Company
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of next-generation abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases.Its products... 
Sector
Pharmaceuticals
Calendar
03/13Earnings Release
More about the company
Surperformance© ratings of Collegium Pharmaceutical I
Trading Rating : Investor Rating :
More Ratings
Latest news on COLLEGIUM PHARMACEUTICAL I
12/06 DEPOMED : Announces NUCYNTA Commercialization Agreement with Collegium Pharmaceu..
12/06 COLLEGIUM PHARMACEUTICAL : Grunenthal GmbH - New partnership for the commerciali..
12/05 COLLEGIUM PHARMACEUTICAL,INC. (NASDA : COLL) Files An 8-K Entry into a Material ..
12/04 COLLEGIUM PHARMACEUTICAL, INC : Entry into a Material Definitive Agreement, Regu..
12/04 Collegium to License Rights to Commercialize Nucynta Franchise
12/04 COLLEGIUM PHARMACEUTICAL,INC. (NASDA : COLL) Files An 8-K Amendments to Articles..
12/04 COLLEGIUM PHARMACEUTICAL, INC : Amendments to Articles of Inc. or Bylaws; Change..
11/22 Collegium to Present at the 29th Annual Piper Jaffray Healthcare Conference
11/08 COLLEGIUM PHARMACEUTICAL : posts 3Q loss
11/08 COLLEGIUM PHARMACEUTICAL : Management's Discussion and Analysis of Financial Con..
More news
Sector news : Pharmaceuticals - NEC
11:03aDJMERCK : Appoints Allan Gabor as Managing Director in China
08:42aDJGLAXOSMITHKLINE : Encouraged By Blood-Cancer Drug Study
07:32aDJSANOFI : Receives U.S. FDA Approval for Insulin Injection Admelog
12:56a Monsanto offers cash to U.S. farmers who use controversial chemical
12/11 ASTRAZENECA : GSK's new pharma head on lookout for cancer deals to boost pipelin..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/11 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
12/06 Collegium Pharmaceutical (COLL) Announces Nucynta Commercialization Agreement..
12/06 COLLEGIUM PHARMACEUTICAL : Updates To Thesis
12/05 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Chart COLLEGIUM PHARMACEUTICAL I
Duration : Period :
Collegium Pharmaceutical I Technical Analysis Chart | COLL | US19459J1043 | 4-Traders
Technical analysis trends COLLEGIUM PHARMACEUTICAL I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 24,2 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Michael Thomas Heffernan Chairman, President & Chief Executive Officer
Joseph J. Ciaffoni Chief Operating Officer & Executive Vice President
Paul Brannelly CFO, Principal Accounting Officer & Executive VP
Alison Fleming Chief Technology Officer
Michael DeGeorge Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
COLLEGIUM PHARMACEUTICAL INC17.79%579
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659